Clinical Trials
69 trialsCisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Beth Israel Deaconess Medical Center
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
Memorial Sloan Kettering Cancer Center
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
City of Hope Medical Center
Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
Dana-Farber Cancer Institute
KEYVIBE-005
Merck Sharp & Dohme LLC
SAFIR02_Breast
UNICANCER
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Hoosier Cancer Research Network
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
The National Center of Oncology, Azerbaijan
NeoURANIA
RenJi Hospital
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
Fudan University
APP
RenJi Hospital
First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients
Fudan University
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
National Cancer Institute, Slovakia
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
Fudan University
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Baylor Research Institute
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
Peking University First Hospital
nonpCR GP
Fudan University
TNBC
Fudan University
Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer
Fudan University
TONIC
The Netherlands Cancer Institute
TONIC-2
The Netherlands Cancer Institute
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
CISPLATIN + AZD-1775 In Breast Cancer
Dana-Farber Cancer Institute
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
Ottawa Hospital Research Institute
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
Massachusetts General Hospital
A-Plus
National Taiwan University Hospital
GEP
Fudan University
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Eli Lilly and Company
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
University of Washington
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
Centre Jean Perrin
Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Massachusetts General Hospital
BERNAQ
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
SHPD001
RenJi Hospital
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
Washington University School of Medicine
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
Emory University
META2
Centre Jean Perrin
Preoperative Cisplatin in Early Stage Breast Cancer
Dana-Farber Cancer Institute
Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer
Washington University School of Medicine
Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy
Russian Academy of Medical Sciences
Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer
Shandong Cancer Hospital and Institute
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
Vanderbilt-Ingram Cancer Center
Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer
Fudan University
Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer
ChineseAMS
BALI-1
Merck KGaA, Darmstadt, Germany